...
首页> 外文期刊>Journal of Cancer Therapy >Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood
【24h】

Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood

机译:荧光微量滴定板快速,简单地分析E6(塔拉泊芬)中的N-天冬氨酰氯及其在细胞,组织和血液中的测定

获取原文

摘要

N-aspartylchlorin e6 (talaporfin) concentrations in cancer cells, mouse liver tissues, and human plasma specimens were determined with fluorescence microtiter plate analysis. Talaporfin standard curves were obtained in each of the sample specimens of cells, mouse tissues, or human plasma including serial concentration of talaporfin. The correlation co-efficiencies (r2) of talaporfin standard curves were 0.99-1.00, and the CV less than 5%. Talaporfin incorporation into cells of human breast cancer cell line MCF-7 after incubating with 25 μg/mL talaporfin for up to 24 h revealed that the t-max of the drug incorporation was approximately 5 h, and the maximum drug concentration incorporated was 25 μg/107 cells. Talaporfin incorporation into MCF-7 cells was significantly decreased in the presence of 3 μg/mL cyc-losporine (p < 0.05). Balb/c nuu mice implanted human cholangiocarcinoma NOZ cells in liver were administered intravenously 5mg/mouse of talaporfin, and the tissues of normal liver and tumor, as well as plasma specimens, were analyzed for talaporfin concentrations. The mean (SD) of talaporfin concentration in plasma after 30 min of administration was 41.6 (2.3) μg/mL, while the level decreased to undetectable concentrations 2 h after administration. In contrast, the talaporfin concentrations in normal and tumor tissues after 30 min of administration were 1.1-7.8 μg/g tissue, and the level slightly increased or was almost maintained for up to 2-4 h after administration. The heparinized blood of the healthy subjects was incubated with 25 μg/mL talaporfin for up to 24 h. The plasma talaporfin concentration did not significantly change during the incubation, and thus talaporfin appears not to be incorporated into the blood cells. We established rapid and simple analysis procedures of talaporfin in biological specimens using a fluorescence microtiter plate assay. Using this assay procedure, the unique pattern of talaporfin disposition and pharmacokinetics were revealed in human cancer cells, liver tissues of tumor bearing mice, and human blood.
机译:用荧光微量滴定板分析法测定癌细胞,小鼠肝组织和人血浆样本中的N-天冬氨酰氯e6(talaporfin)浓度。在细胞,小鼠组织或人血浆的每个样品标本中都获得了塔拉泊芬标准曲​​线,包括塔拉泊芬的系列浓度。他拉泊芬标准曲​​线的相关系数(r2)为0.99-1.00,CV小于5%。在与25μg/ mL他拉泊芬孵育24小时后,将Talaporfin掺入人乳腺癌细胞系MCF-7的细胞中显示,药物掺入的t-max约为5 h,掺入的最大药物浓度为25μg / 107个单元格。在3μg/ mL的cyc-losporine存在下,Talaporfin掺入MCF-7细胞的比例显着降低(p <0.05)。对在肝脏中植入人胆管癌NOZ细胞的Balb / c nu / nu小鼠静脉注射5mg /小鼠他拉泊芬,并分析正常肝脏和肿瘤组织以及血浆标本中他拉泊芬的浓度。给药后30分钟血浆中他拉泊芬的平均浓度(SD)为41.6(2.3)μg/ mL,而给药后2小时该水平降至无法检测的浓度。相比之下,给药后30分钟,正常组织和肿瘤组织中他拉泊芬的浓度为1.1-7.8μg/ g组织,给药后水平在2-4小时内略有增加或几乎保持不变。将健康受试者的肝素化血液与25μg/ mL他拉泊芬孵育长达24小时。在孵育过程中血浆他拉泊芬浓度没有明显变化,因此他拉泊芬似乎未掺入血细胞中。我们使用荧光微量滴定板测定法建立了生物样品中他拉泊芬的快速,简单分析程序。使用该测定方法,在人类癌细胞,荷瘤小鼠的肝组织和人类血液中揭示了他拉泊芬配置和药代动力学的独特模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号